MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Sumatriptan

Selected References:

  • Amundsen S, et al. 2015. Pharmacological treatment of migraine during pregnancy and breastfeeding; Nat. Reviews Neurol; 11(4): 209-215.
  • Bandoli G, et al. 2020. Migraines During Pregnancy and the Risk of Maternal Stroke. JAMA Neurol; 77(9):1177-79.
  • Bánhidy F, et al. 2006. Maternal severe migraine and risk of congenital limb deficiencies. Birth Defects Res a Clin Mol Teratol; 76(8):592-601.
  • Cunnington M, et al. 2009. The safety of sumatriptan and naratriptan in pregnancy: what have we learned? Headache; 49(10):1414-22.
  • David PS, et al. 2014. Migraine in pregnancy and lactation. Curr Neurol Neurosci Rep; 14(4):439.
  • Duong S, et al. 2010. Safety of triptans for migraine headaches during pregnancy and breastfeeding. Can Fam Physician; 56(6):537-9.
  • Ephross AS, et al. 2014. Final results from the 16 year sumatriptan, naratriptan, and treximet pregnancy registry. Headache; 54(3):1158-1172.
  • Harris GE, et al. 2018. Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: Follow-up from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol. 2018 May;32(3):247-255.
  • Jarvis S, et al. 2018. Managing migraine in pregnancy. BMJ 360:k80.
  • Källén B, et al. 2011. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf; 34(8):691-703.
  • MacGregor AE, et al. 2014. Migraine in pregnancy and lactation. Neurol Sci; 35(Suppl 1): S61-S64.
  • Marchenko A, et al. 2015. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis. Headache; 55(10):1478.
  • Miller C & Vollbracht S. 2021. Neurology of Preeclampsia and Related Disorders: an Update in Neuro-obstetrics. Curr Pain Headache Rep; 25(6):40.
  • Negro A, et al. 2017. Headache and pregnancy: a systematic review. The Journal of Headache and Pain; 18(1):106.
  • Nezvalová-Henriksen K, et al. 2010. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study. Headache; 50(4):563-75.
  • Nezvalová-Henriksen K, et al. 2013. Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol; 28(9):759-69.
  • Olesen C, et al. 2000. Pregnancy outcome following prescription for sumatriptan. Headache; 40(1):20-4.
  • Spielmann K, et al. 2018. Pregnancy outcome after anti-migraine triptan use: a prospective observational cohort; Cephalagia 38(6):1081-1092.
  • Wabnitz A, Bushnell C. 2015. Migraine, cardiovascular disease, and stroke during pregnancy: systematic review of the literature. Cephalalgia; 35(2):132-9.
  • Wojnar-Horton RE, et al. 1996. Distribution and excretion of sumatriptan in human milk. Br J Clin Pharmacol; 41(3):217-21.
  • Wood ME, et al. 2016. Prenatal Triptan Exposure and Internalising and Externalising Behaviour Problems in 3-Year-Old Children: Results from the Norwegian Mother and Child Cohort Study. Paediatr Perinat Epidemiol; Mar;30(2):190-200.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.